SAGE Therapeutics’ GABA Receptor–Based Portfolio
As we discussed earlier, SAGE Therapeutics’ (SAGE) portfolio includes the products it has under development for the treatment of life-threatening central nervous system disorders based on either GABA (gamma-Aminobutyric acid) or NMDA (N-methyl-D-aspartate) receptor systems.